Cell-penetrating peptides as delivery enhancers for vaccine

Current Pharmaceutical Biotechnology

Volumn 15, Issue 3, 2014, Pages 256-266

  Jiang, Yuhong ^a   Li, Man ^a   Zhang, Zhirong ^a   Gong, Tao ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Administration route; Antigenic cargo; Cell penetrating peptide; Vaccine delivery

Indexed keywords

CELL PENETRATING PEPTIDE; CLATHRIN; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PENETRATION ENHANCING AGENT; VACCINE; ANTIGEN; CAVEOLIN 1; CD4 ANTIGEN; CHOLESTEROL; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; TRANSACTIVATOR PROTEIN;

ANTIGEN PRESENTATION; CAVEOLA; CELL MEMBRANE PERMEABILITY; ENDOCYTOSIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INTERNALIZATION; MEMBRANE POTENTIAL; NONHUMAN; PINOCYTOSIS; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; TRANSPORT AT THE CELLULAR LEVEL; ARTICLE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG PENETRATION; DRUG UPTAKE; HERPES SIMPLEX VIRUS 1; LIPID BILAYER; MARDIVIRUS; PHYSICAL CHEMISTRY; TUMOR IMMUNITY; VIRUS IMMUNITY;

ANIMALS; ANTIGENS; BIOLOGICAL TRANSPORT; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; VACCINES;

EID: 84907366301     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140813130114     Document Type: Review

References (125)

1. Maria L.; Mattias H.; Alain P.; Ülo L. Cell-penetrating peptides. Trends Pharmacol Sci., 2000, 21(3), 99-103.
2. Jean P. R.; Kamran M.; Eric V.; Corinne R.; Birgit V.; Mike J. G.; Leonid V. C.; Bernard L. Cell-penetrating peptides A reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 2003, 278, 585-590.
3. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L.L.; Pepinsky, B.; Barsoum, J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA, 1994, 91(2), 664-668.
4. Mauricio, R.; John, P.D.; Zhongjia, T.; Yao-Zhong, L. Genetic engineering of proteins with cell membrane permeability. Nat. Biotech., 1998, 16, 370-375
5. Pero, S.C.; Shukla, G.S.; Cookson, M.M.; Flemer, Jr. S.; Krag, D.N. Combination treatment with Grb7 peptide and doxorubicin or trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br. J. Cancer., 2007, 96, 1520-1525.
6. Crombez, L.; Aldrian-Herrada, G.; Konate, K.; Nguyen, Q.N.; McMaster G.K.; Brasseur R.; Heitz F.; Divita G. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther., 2009, 17, 95-103
7. Moschos, S.A.; Jones, S.W.; Perry, M.M.; Williams, A.E.; Erjefalt, J.S.; Turner, J.J.; Barnes, P.J.; Sproat, B.S.; Gait, M.J.; Lindsay, M.A. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem., 2007, 18, 1450-1459
8. Berry, C.C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomed, 2008, 3, 357-365.
9. Limin, P.; Qianjun, H.; Jianan, L.; Yu, C.; Ming, M.; Linlin, Z.; Jianlin, S. Nuclear-targeted drug delivery of TAT peptideconjugated monodisperse mesoporous silica nanoparticles. J. Am. Chem. Soc., 2012, 134(13), 5722-5725.
10. Carsten, R.; Ulrike, S.; Aurora, O.; Kerstin, T.; Christian, P.; Rainer, H. M.; Joseph, R. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TATpeptide in vitro and in vivo. Pharm. Res., 2004, 21(9), 1662-1669.
11. Gang, R.; Amit, A.; Adam, I.M.; Shuming, N. Imaging and Tracking of Tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J. Am. Chem. Soc., 2007, 129, 14759-14766
12. Chen, B.; Liu, Q.; Zhang, Y.; Xu, L.; Fang, X. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir, 2008, 24, 11866-11871.
13. Frankel, A.D.; Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55, 1189-1193.
14. Green, M.; Loewenstein, P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell, 1988, 55, 1179-1188.
15. Bhawna G.; Tatiana S.L.; Vladimir P.T. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev., 2005, 57, 637-651
16. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 1997, 272, 16010-16017.
17. Nicole, A. B.; Dodie, S. P.; Choon-Kit, T.; Vasso, A.; Geoffrey A. P. Cell-penetrating peptides: Application in vaccine delivery. Biochim. Biophys. Acta, 2010, 1805, 25-34.
18. Derossi, D.; Jolio, T.A.H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 1994, 269, 10444-10450.
19. Elliott, G.; O'Hare, P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell, 1997, 88, 223-233.
20. Oehlke, J.; Scheller, A.; Wiesner, B.; Krause, E.; Beyermann, M.; Klauschenz, E.; Melzig, M.; Bienert, M. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta, 1998, 1414, 127-139.
21. Morris, M.C.; Depollier, J.; Mery, J.; Heitz, F.; Divita, G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol., 2001, 19, 1173-1176.
22. Green, M.; Ishino, M.; Loewenstein, PM. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of transdominant mutants that suppress HIV-LTR-driven gene expression. Cell, 1989, 58, 215-223.
23. Angela, D R.; Rashida, A M.; Jean, C. Cellular import mediated by nuclear localization signal peptide sequences. Chem. Biol., 2002, 9, 943-948.
24. Morris, M. C.; Vidal, P.; Chaloin, L; Heitz, F.; G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res., 1997, 25, 2730-2736.
25. Margus, P.; Mattias, H.; Matjal, Z.; Uumllo, L. Cell penetration by transportan. FASEB J., 1998, 12, 67-77.
26. Rhee, M.; Davis, P. Mechanism of uptake of C105Y, a novel cellpenetrating peptide. J. Biol. Chem., 2006, 281, 1233-1240.
27. Jessica, R. M.; Jesse, P.; Kalina, H.; William, C. W. Department of Biochemistry, T Spontaneous membrane-translocating peptides by orthogonal high-throughput screening. J. Am. Chem. Soc., 2011, 133, 8995-9004.
28. Milletti, F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today, 2012, 17, 850-860.
29. Arwyn T.J.; Edward J.S. Cell entry of cell penetrating peptides: tales of tails wagging dogs. J. Control Release, 2012, 161, 582-591
30. Derek, T.O.H.; Rino, R. Novel approaches to vaccine delivery. Pharmaceut. Res., 2004, 21(9), 1519-1530.
31. Martin F.B.; Gary T.J. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol., 2010, 10, 787-796.
32. Schutze-Redelmeier, M.P.; Gournier, H.; Garcia-Pons, F.; Moussa, M; Joliot, A.H.; Volovitch, M.; Prochiantz A.; Lemonnier F.A. Introduction of exogenous antigens into the MHC Class I processing and presentation pathway by Drosophila Antennapedia Homeodomain primes cytotoxic T cells in vivo. J. Immunol., 1996, 157, 650-655.
33. Kim, D.T.; Mitchell, D.J.; Brockstedt, D.G.; Fong, L.; Nolan, G. P.; Fathman, C. G.; Engelman, E. C.; Rothbard J. B. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol., 1997, 159, 1666-1668
34. Lu, J.; Wettstein, P.J.; Higashimoto, Y.; Appella, E.; Celis, E. TAP-independent presentation of CTL epitopes by Trojan antigens. J. Immunol., 2001, 166, 7063-7071.
35. Pouniotis, D.S.; Apostolopoulos, V.; Pietersz, G.A. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology, 2006, 117, 329-339.
36. Ira, M. Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol., 1996, 12, 575-625.
37. Sean D.C.; Sandra L. S. Regulated portals of entry into the cell. Nature, 2003, 422, 37-44.
38. Arwyn, T.J. Macropinocytosis: Searching for an endocytic identity and a role in the uptake of cell penetrating peptides. J. Cell. Mol. Med., 2007, 11(4), 670-684.
39. Ikuhiko, N.; Akiko, T.; Noriko, K.; Toshihide, T.; Hironori, K.; Kiyo, H.; Manabu, N.; Motoyoshi, N.; Yukio, S.; Shiroh, F. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochem, 2007, 46, 492-501.
40. Jean, P.R. Cellular Uptake of Unconjugated TAT Peptide Involves Clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem., 2005, 280, 15300-15306.
41. Fittipaldi, A.; Ferrari, A.; Zoppe, M.; Arcangeli, C.; Pellegrini, V.; Beltram F.; Giacca, M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 tat fusion proteins. J. Biol. Chem., 2003, 34141-34149.
42. Vandenbroucke, R.E.; De Smedt, S.C.; Demeester J.; Sanders, N.N. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes, Biochim. Biophys. Acta, 2007, 1768, 571-579.
43. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cellpenetrating peptides. Traffic, 2007, 8, 848-866.
44. Deshayes, S.; Plénat, T.; Aldrian-Herrada, G.; Divita, G.; Le Grimellec, C.; Heitz, F. Primary amphipathic cell-penetrating pep tides: structural requirements and interactions with model membranes. Biochem, 2004, 43, 7698-7706.
45. Dupont, E.; Prochiantz A.; Joliot, A. Identification of a signal peptide for unconventional secretion. J. Biol. Chem., 2007, 282, 8994-9000.
46. Anna E.; Mats H.; Ülo L. Structure-activity relationship study of the cell-penetrating peptide pVEC. Biochim. Biophys. Acta, 2006, 1758(6), 721-729.
47. Fatemeh M.; Staffan L.; Ulo L.; Shiroh F.; Astrid G. Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. J. Biophys., 2011, 414-729.
48. Judith, M.; Ines, K.; Rudolf, V.; Prisca, B. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjugate Chem., 2008, 19, 2363-2374.
49. Guillaume D.; Sylvine C.; Emmanuelle B.; Anthony R.R.; Jamal T. Studies on the internalization mechanism of cationic cellpenetrating peptides. J. Biol. Chem., 2003, 278, 31192-31201.
50. Dana M.C.; Kent L.; Elo E.; Ülo L. Cell-Penetrating Peptides: Design, Synthesis, and Applications. ACS Nano., 2014, 8(3), 1972-1994.
51. Gisela, T.; Robert, M.M.; Simone, H.; Christoph, P.; Frank, E.; Cristina, C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB, 2006, 20, 1778-1784.
52. Ikuhiko, N.; Miki, N.; Toshihide, T.; Kazuhiro, S.; Noriko, K.; Yukihiro, K.; Masanori, T.; Seigo, T.; Kunihiro, U.; Jeremy, C.S.; Arwyn, T.J.; Yukio, S.; Shiroh, F. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther., 2004, 10(6), 1011-1022.
53. Feihu, W.; Yun, W.; Xiao, Z.; Wenjun, Z.; Shengrong G.; Fang J. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J. Control Release, 2014, 174, 126-136
54. Ian, M.K.; Jehangir, S.W.; Steven, F.D. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control Release, 2005, 102, 247-253.
55. Seyed, A.M. Clathrin-dependent endocytosis. Biochem. J., 2004, 377, 1-16.
56. Simon, W.J.; Richard, C.; Ken, B.; Catherine, J.V.; Sarah, M.V.B.; Peter, N.; Mark A.L. Characterisation of cell-penetrating peptidemediated peptide delivery. Br. J. Pharmacol., 2005, 145, 1093-1102.
57. Ferrari, A. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther., 2003, 8, 284-294.
58. Campbell, S.M.; Crowe, S.M.; Mak, J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J. Clin. Virol., 2001, 22, 217-227.
59. Sonali, B.F.; Mark, P.P.; Shana, O.K. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev., 2009, 61, 953-964.
60. Eric, V.; Julien S.; André, P. Cell penetrating and cell targeting peptides in drug delivery. Biochim. Biophys. Acta, 2008, 1786(2), 126-38.
61. Thoren, P.E.; Persson, D.; Esbjorner, E.K.; Goksor, M.; Lincoln P.; Norden, B. Membrane binding and translocation of cell-penetrating peptides. Biochem., 2004, 43, 3471-3489.
62. Thoren, P.E.; Persson, D.; Lincoln, P.; Norden, B. Membrane destabilizing properties of cell-penetrating peptides. Biophys. Chem., 2005, 114, 169-179.
63. Anna, R.; Sébastien, D.; Karidia, K.; Laurence, C.; Kärt, P.; Hassan, B.; Gudrun, A.; Margus, P.; Gilles, D. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. Plos One, 2011, 6(10), 25924.
64. Schutze-Redelmeier, M.P.; Gournier, H.; Garcia-Pons, F.; Moussa, M; Joliot, A.H; Volovitch, M.; Prochiantz A.; Lemonnier F.A. Introduction of exogenous antigens into the MHC Class I processing and presentation pathway by Drosophila Antennapedia Homeodomain primes cytotoxic T cells in vivo. J. Immunol., 1996, 157, 650-655.
65. Pietersz, G.A.; Li, W.; Apostolopoulos, V.; A 16-mer peptide, (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the class I pathway. Vaccine, 2001, 19, 1397-1405.
66. Naotaka, S.; Mark C.U. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J. Immunol., 2002, 168, 2393-2401.
67. Helen, Y.W.; Tihui, F.; Gang, W.; Gang, Z.; Donna, M. Perry-L.; James, C.Y.; Nicholas, P.R.; Patrick, H.; Rong-Fu, W. Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest., 2002, 109, 1463-1470.
68. Yang, Z.; Wang, L.; Wang, H.; Shang, X.; Niu, W.; Li, J.; Wu, Y. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Mol. Immunol., 2008, 45, 1674-1681.
69. Apostolopoulos, V.; Pouniotis, D.S.; van Maanen, P.J.; Andriessen, R.W.; Lodding, J.; Xing, P.-X; McKenzie, I.F.C.; Loveland, B.E.; Pietersz, G.A. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine, 2006, 24, 3191-3202.
70. Chikh, G.; Bally, M.; Schutze-Redelmeier, M.P. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J. Immunol. Methods, 2001, 254, 119-135.
71. Shibagaki, N.; Udey, M.C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur. J. Immunol., 2003, 33, 850-860.
72. Carsten T.V.; Yoshiyuki T.; Tingting C.; Daniel M.F.; Andrew T.; Timothy P.F.; Timothy J.E.; Peter, S. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Res. Tr., 2005, 91, 271-278.
73. Justesen, S.; Buus, S.; Claesson, M.H.; Pedersen, A.E. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice. Immunol., 2007, 122, 326-334.
74. Ghania, G.C.; Spencer, K.; Marcel, B.B.; Jean-Claude, M.; Marie-Paule, M.S-R. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J. Immunol., 2001, 167, 6462-6470.
75. Hiroshi, M.; Takashi, I.; Reiko, K.; Naotaka, S.; Shinji, S. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC Class I and Class II and elicits superior antitumor immunity. J. Invest. Dermatol., 2006, 126, 1804-1812.
76. Hyun-Il, C.; Eun-Kyung, K.; Soo-Young, P.; Su Kyung, L.; Yong-Kil, H.; Tai-Gyu, K. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett., 2007, 258, 189-198.
77. Gicheru, M. M.; Tinega, A. N.; Pellé, R.; Kang'a, S.; Taracha, E. L.; Nene, V.; Graham, S. P. Fusion of a cell penetrating peptide from HIV-1 TAT to the Theileria parva antigen Tp2 enhances the stimulation of bovine CD8+ T cell responses. Vet. Immunol. Immunop., 2009, 130, 107-113.
78. Bao, Z.; Yanzhong, W.; Yu, Z.; Yang, L.; Xiaojun, Z.; Yaxing, X.; Lizhao, C.; Changfei, L.; Ying, J.; Songdong M. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses. Vaccine, 2013, 31, 545-552.
79. Nicole, A. B.; Dodie, S. P.; Kuo-Ching, S.; Vasso, A.; Geoffrey A. P. A membrane penetrating multiple antigen peptide (MAP) incorporating ovalbumin CD8 epitope induces potent immune responses in mice. Biochim. Biophys. Acta, 2010, 1798, 2286-2295.
80. Jason, R.; Christian, H.O.; Freda, K.S. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer, 2008, 8, 108-120.
81. Hashida, H.; Miyamoto, M.; Cho, Y.; Hida, Y.; Kato, K.; Kurokawa, T.; Okushiba, S.; Kondo, S.; Dosaka-Akita, H.; Katoh H. Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool. Br. J. Cancer, 2004, 90, 1252-1258.
82. Tae Woo, K.; Chien-Fu, H.; Jeong Won, K.; Jeremy, J.; Pei-Jer, C.; Liangmei, H.; David, A.K. B.; Wu, T.-C. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum. Gene Ther., 2004, 15, 167-177.
83. Liangmei, H.; Jeremy, J.; Tzyy-Jye, L.; Morris, L.; Wu, T.-C. Improving DNA vaccine potency by linking Marek's disease virus Type 1 VP22 to an antigen. J. Virol., 2002, 76(6), 2676-2682.
84. Waithaka, M.; Wendy, C.B.; Gary, A.S.; Yan, Z.; Kimberly, K.; Guy, H. P. Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection. J. Leukocyte Bio., 2005, 78, 401-411.
85. Stuart, D.P.; Gill, H.; Roman, A.L.; Robert, J.P.; Freda, K.S.; Alice, M.B. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine, 2005, 23, 1931-1940.
86. Stuart, D.P.; Helen, C.; Flick, S.; Helen, S.G.; Angela, E.E.; Freda, K.S.; Robert, J.P. Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax. Genetic Vaccines Ther., 2005, 3, 3.
87. Sterghios, A.M.; Simon, W.J.; Mark, M.P.; Andrew, E.W.; Jonas, S.E.; John, J.T.; Peter, J.B.; Brian, S.S.; Michael, J.G.; Mark, A.L. Lung delivery studies using siRNA conjugated to TAT (48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjugate Chem., 2007, 18, 1450-1459.
88. Glenn, G.M.; Kenney, R.T. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol., 2006, 304, 247-268.
89. Partidos, C.D.; Beignona, A.-S.; Mawasb, F.; Belliarda, G.; Brianda, J.-P.; Mullera, S. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine, 2003, 21, 776-780.
90. Saman, A.N.; Noriyasu, K.; Mariko, Takeda-M. Cell-penetrating Peptides as a novel transdermal drug delivery system. Chem. Biol. Drug Des., 2012, 80, 639-646.
91. Rothbard, J.B.; Garlington, S.; Lin, Q.; Kirschberg, T.; Kreider, E.; McGrane, P.L; Wender, P.A.; Khavari, P.A. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med., 2000, 6, 1253-1257.
92. Park, J.; Ryu, J.; Jin, L.H.; Bahn, J.H.; Kim, J.A.; Yoon, C.S.; Kim, D.W.; Han, K.H.; Eum, W.S.; Kwon, H.Y.; Kang, T.C.; Won, M.H.; Kang, J.H.; Cho, S.W.; Choi, S.Y. 9-polylysine protein transduction domain: Enhanced penetration efficiency of superoxide dismutase into mammalian cells and skin. Mol. Cells, 2002, 13, 202-208.
93. Eum, W.S.; Jang, S.H.; Kim, D.W.; Choi, H.S.; Choi, S.H.; Kim, S.Y.; An, J.J.; Lee, S.H.; Han, K.; Kang, J.H.; Kang, T.C.; Won, M.H.; Cho, Y.J.; Choi, J.H.; Kim, T.Y.; Park, J.; Choi, S.Y. Enhanced transduction of Cu, Zn-superoxide dismutase with HIV-1 Tat protein transduction domains at both termini. Mol. Cells, 2005, 19, 191-197.
94. Luciana, B.L.; Colleen, M.B.; Elizabeth, F.; Charles, R.F.; Olivia, S.; Padmini, K.; Lokesh, J.; Alyssa, P.M., Vitoria, L.B.B. Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Pharm. Res., 2005, 22(5), 750-757.
95. Pinaki, D.; Ram, R.P.; Mandip, S. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol. Membr. Bio., 2010, 27(7), 247-259.
96. Schutze-Redelmeier, M.P.; Kong, S.; Bally, M.B.; Dutz, J.P. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine, 2004, 22, 1985-1991.
97. Paul H.L.; Philippe, E.L. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine, 2008, 26, 3197-3208.
98. Xiaohua, C.; Jinglan, L.; Qingchun, P.; Zhenghao, T.; Yongsheng, Y.; Guoqing, Z. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. Vaccine, 2010, 28, 3913-3919.
99. Milaid, G.; Maribel, G.V.; Aileen, B.; Osmany, M.; Yordanka, S.; Victoria, M.L.; Isis, T. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine, 2011, 29, 920-930.
100. Jun, T.; Yin, R.; Tian, Y.; Huang, Z.; Shi, J.; Fu, X.; Wang, L.; Wu, Y.; Hao, F.; Ni, B. A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent antitumor immunity in mice. Vaccine, 2012, 30, 1071-1082.
101. El-Sayed, K.; Noriyasu, K.; Mariko, T-M. Cell-penetrating Peptide-biodrug strategy for oral and nasal delivery: Review of recent findings. J. Exp. Clin. Med., 2012, 4(4), 198-202.
102. Marian, R.N.; Pamela, A.K. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol., 2006, 6, 148-158.
103. Takanori, K.; Hiroyuki T.; Ko, T.; Yuuki, T.; Hiroaki, O. Cellpenetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm. Res., 2011, 28, 2130-2139.
104. El-Sayed, K.; Mariko, M.; Koichi, I.; Jun, I.; Kozo, T. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control Release, 2009, 133, 103-108.
105. El-Sayed, K.; Mariko, M.; Noriyasu, K.; Yoshimi, E.; Yohei, I.;, Kozo, T. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm., 2009, 381, 49-55.
106. Shinji, S.; Masaya, S.; Saki, I.; Yoko, M.; Kazuhiro, N.; Yoshie, M.; Makoto, K.; Shinji, Y.; Noriko, N.; Norihiro, S.; Hitoshi, Y.; Ken-ichiro, H.; Hiroyuki, T.; Ryoji, K.; Tomofumi, U.; Masanori, B. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Mol. Pharm., 2012, 9, 2933-2941.
107. Takanori, K.; Yuuki, T.; Yasunori, S.; Miki, T.; Toshiaki, T.; Hiroaki, O. Effective vaginal DNA delivery with high transfection efficiency is a good system for induction of higher local vaginal immune responses. J. Pharm. Pharmacol., 2009, 61, 1457-1463.
108. Kanazawa T.; Takashima, Y.; Hirayama, S.; Okada H. Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine. Int. J. Pharm., 2008, 360, 164-170.
109. Yi, Z.; Jian-Fang, N.; Xing-qin, Q.; Xiao-Lin, M.; Jin-Ping, X. TAT-mediated oral subunit vaccine against white spot syndrome virus in crayfish. J. Virol. Methods, 2012, 181, 59-67.
110. Hanke, T.; Blanchard, T.J.; Schneider, J.; Ogg, G.S.; Tan, R.; Becker, M.; Gilbert, S.C.; Hill, A.V.; Smith, G.L.; McMichael, A. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol., 1998, 79, 83-90.
111. Bleifuss, E.; Kammertoens, T.; Hutloff, A.; Quarcoo, D.; Dorner, M.; Straub, P.; Uckert, W.; Hildt, E. The translocation motif of hepatitis B virus improves protein vaccination. Cell Mol. Life Sci., 2006, 63, 627-635.
112. Gisela, T.; Gohar, Ter-A.; Robert, M.M.; Martin, S.; Andreas, H.; M. Cristina, C. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J. Pept. Sci., 2008, 14, 469-476.
113. Nan, Y.H.; Park, I.S.; Hahm, K.S.; Shin, S.Y. Antimicrobial activity, bactericidal mechanism and LPS-neutralizing activity of the cell-penetrating peptide pVEC and its analogs. J. Pept. Sci., 2011, 17, 812-817.
114. Amir, A.M.; Semi, K.; Yunhee, L.; Bong Hyun, C.; Myung K.L. Novel cell penetrating peptides with multiple motifs composed of RGD and its analogs. Biochem. Biophy. Res. Co, 2013, 432, 359-364.
115. Nakayama, F.; Takeshi, Y.; Sachiko, U.; Masahiro, A.; Toru, I.; Viktor, M.; Makoto A. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cellpenetrating peptide domain. J. Biol. Chem., 2011, 286, 25823-25834.
116. Langedijk, J.P.M.; Olijhoek, T.; Meloen R.H. Application, efficiency and cargo-dependence of transport peptides. Int. Congr. Ser., 2005, 1277, 95-107.
117. Xiang, X.; Xia, F.; Chun, Z.; Qiang, W.; Xi, W.; Wei, G.; Wei, X.; Jian, Y.; Jing-Long, Y.; Hua-Ping, L. A cell-penetrating peptide suppresses inflammation by inhibiting NF-[kappa]B signaling. Mol. Ther. 2011, 19, 1849-1857.
118. Masayuki, M.; Shinichi, M.; Yun-Fei, L.; Hideki, M.; Susan Bonner-W. Mechanism of PDX-1 protein transduction. Biochem. Biophys. Res. Commun., 2005, 332, 68-74.
119. Bartlett, R.L.; Panitch, A. Thermosensitive nanoparticles with pHtriggered degradation and release of anti-inflammatory cellpenetrating peptides, Biomacromolecules, 2012, 13, 2578-2584.
120. Catherine, D.E.C.; Antonio, F.; Vanessa, C.; Matthieu, M.; Sophie, C.; Ennio, T.; Audrey, D.; Denis, R.; Jonathan, K.; Mauro, G.; Françoise, C. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem. J., 2005, 390, 407-418.
121. Oehlke, J.; Eberhard, K.; Burkhard, W.; Michael, B.; Michael, B. Extensive cellular uptake into endothelial cells of an amphipathic β-sheet forming peptide. FEBS Lett., 1997, 415, 196-199.
122. El-Andaloussi, S.; Henrik, J.J.; Tina, H.; Ülo, L. A novel cellpenetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol. Ther., 2007, 15, 1820-1826.
123. Kamide, K.; Hiroshi, N.; Shusei, U.; Akiyoshi, F. Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and theirmodifications. Int. J. Mol. Med., 2010, 25, 41-51.
124. Rhee, M.; Davis, P. Mechanism of uptake of C105Y, a novel cellpenetrating peptide. J. Biol. Chem., 2006, 281, 1233-1240.
125. Gao, S.; Simon, M.J.; Hue, C.D.; Morrison B.; Banta, S. An unusual cell penetrating peptide identified using a plasmid displaybased functional selection platform, ACS Chem. Biol., 2011, 6, 484-491.